ARGENX Platform trial About this clinical research study: Adapt Forward is a platform of studies designed for people living with MG. It consists of several studies that are meant to evaluate how different combinations and regimens of MG drugs may work (also known as efficacy) and how safe they are for the use in adults […]
ARGENX Platform trial Read More »
ANNOVIS Alzheimer’s Disease What is the ANNOVIS Alzheimer’s Disease Study? A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD The Goal The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer’s disease in adults aged 55-85. It will also learn about the safety
ANNOVIS Alzheimer’s Disease Read More »
Roche/Genentech PARAISO Why is the study needed? Paraiso is study to compare prasinezumab with a placebo in people with early-stage Parkinson’s disease who are taking levodopa to manage their disease symptomsParkinson’s disease (PD) is a long-term condition that gets worse over time. In PD, a naturally occurring protein called alpha-synuclein does not form properly. It sticks together
Roche/Genentech PARAISO Read More »
Cartesian Aurora What is the AURORA Study? The aim of the AURORA Study is to assess the safety and effectiveness of an mRNA CAR T-cell therapy, known as Descartes-08, as a potential approach to treat generalized myasthenia gravis. Myasthenia gravis is an autoimmune disease, which means that the immune system mistakenly produces antibodies (proteins that
Novartis “Relieve” We are assessing the effectiveness and safety of remibrutinib, an investigational medicine being developed for people who have generalized Myasthenia Gravis (gMG). Click here for More Information Inclusion Criteria: – Have a confirmed, documented diagnosis of gMG: either positive for AChR+ antibody or MuSK+ antibody, or seronegative for both AChR and MuSK antibodies
Novartis “Relieve” Read More »
ArgenX Empassion The Empassion study is designed to assess how safe and effective an investigational study drug, empasiprubart, is compared to intravenous immunoglobulin (IVIg) as a possible treatment for adults living with multifocal motor neuropathy (MMN). The clinical study is looking to enroll up to 100 participants across the world. Enrolled participants will be asked
Supernus RENAISSANCE 2 Please see below for Epilepsy Research Opportunity. For more information please contact: Jacara WashingtonClinical Research CoordinatorP: 716-961-9220E: jawashington@dentinstitute.com
Supernus RENAISSANCE 2 Read More »
Sanofi VITALIZE A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will
TG ENABLE The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting. Inclusion Criteria: Participants with a confirmed Multiple Sclerosis (MS) diagnosis who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion. For more
TEVA IMPACT TD Registry (Tardive Dyskinesia) The purpose of this study is to uncover how tardive dyskinesia (TD) develops over time and its impact on individuals. Inclusion Criteria: Patients who are newly initiating deutetrabenazine as part of routine clinical practice. What to Expect As part of your usual care, you will complete questionnaires and visit
